- Chemical Formula: C17H23Cl2NO
- Molecular Mass: 328.3
- Other Names: NS-2330, UNII-BLH9UKX9V1, BLH9UKX9V1, ZINC3953158
- CAS Number: 195875-84-4
- PubChem: 11370864
- Total Amount of the Active Ingredient: 500 mcg/capsule
- Shelf Life: 36 months
Tesofensine is a reuptake inhibitor that increases the availability of serotonin, noradrenaline, and dopamine in the brain. It functions by inhibiting the neurotransmitters in the brain associated with hunger and appetite.
Tesofensine is being studied extensively to see if it could be used to treat neurological conditions such as Parkinson’s and ADHD. In animal trials, effects on motor function and cognitive function improved in the respective disease models. From these trials, the subject models began to lose too much weight, and now researchers are determining its potential to treat obesity. Several clinical trials have been done to show its promising potential to treat obesity and it has since been in phase II trials.
All of our products are lab tested and the results are occasionally published on the website.
You can have the product you bought from us tested at any HPLC-licensed testing facility and if the results are negative, we will refund the following:
- Cost of HPLC test
- Total amount of the order + shipping fee
Independent Test Results
All of our products are lab tested and the results are periodically published on the website.
- Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
Axel, A. M., Mikkelsen, J. D., & Hansen, H. H. (2010). Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 35(7), 1464–1476. https://doi.org/10.1038/npp.2010.16
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
Astrup, A., Madsbad, S., Breum, L., Jensen, T., Kroustrup, J. P., & Larsen, T. M. (2008). The Lancet, 372(9653), 1906–1913. https://doi.org/10.1016/s0140-6736(08)61525-1